Northwest Biotherapeutics, Inc.
NWBO
$0.19
-$0.01-4.43%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.50M | 1.38M | 937.00K | 1.09M | 1.47M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.50M | 1.38M | 937.00K | 1.09M | 1.47M |
| Cost of Revenue | 25.29M | 28.79M | 33.75M | 34.43M | 35.30M |
| Gross Profit | -23.80M | -27.41M | -32.82M | -33.34M | -33.82M |
| SG&A Expenses | 29.71M | 32.51M | 32.09M | 32.05M | 34.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.00M | 61.29M | 65.85M | 66.48M | 69.55M |
| Operating Income | -53.50M | -59.91M | -64.91M | -65.39M | -68.08M |
| Income Before Tax | -44.43M | -60.70M | -89.77M | -82.32M | -84.81M |
| Income Tax Expenses | -537.00K | -537.00K | -- | -- | -- |
| Earnings from Continuing Operations | -43.89 | -60.16 | -89.77 | -82.32 | -84.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.89M | -60.16M | -89.77M | -82.32M | -84.81M |
| EBIT | -53.50M | -59.91M | -64.91M | -65.39M | -68.08M |
| EBITDA | -51.10M | -57.85M | -63.14M | -63.62M | -66.33M |
| EPS Basic | -0.03 | -0.04 | -0.07 | -0.06 | -0.07 |
| Normalized Basic EPS | -0.02 | -0.03 | -0.03 | -0.03 | -0.04 |
| EPS Diluted | -0.03 | -0.05 | -0.07 | -0.07 | -0.07 |
| Normalized Diluted EPS | -0.02 | -0.03 | -0.03 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 6.05B | 5.83B | 5.60B | 5.36B | 5.14B |
| Average Diluted Shares Outstanding | 6.05B | 5.83B | 5.60B | 5.36B | 5.14B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |